Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.

EBioMedicine - 1 Apr 2021

Kaoutari Abdessamad El, Fraunhoffer Nicolas A, Hoare Owen, Teyssedou Carlos, Soubeyran Philippe, Gayet Odile, Roques Julie, Lomberk Gwen, Urrutia Raul, Dusetti Nelson, Iovanna Juan

Abstract excerpt

BACKGROUND: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease. METHODS: In this study, we perform the metabolomics profiling of 77 PDAC patient-derived tumor xenografts (PDTX)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Databases, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple

Share to Drug Resistance, Neoplasm

Share to Lipid Metabolism

Share to Metabolome

Share to Metabolomics

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33862584
DOI: 10.1016/j.ebiom.2021.103332
PMCID: PMC8054161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.PMID 33862584Read ↗

Metabolomic profiling of pancreatic adenocarcinoma reveals fundamental clinical featuresSemantic proximity Read ↗

Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read ↗

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma ClassificationSemantic proximity Read ↗

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read ↗

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic predictionSemantic proximity Read ↗

Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profilesSemantic proximity Read ↗

Subtype specific metabolic vulnerabilities in pancreatic cancerSemantic proximity Read ↗

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)Semantic proximity Read ↗

Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer.Semantic proximity Read ↗

The Intricate Metabolism of Pancreatic Cancers.Semantic proximity Read ↗

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.